TriSalus Life Sciences, Inc. Stock-Based Compensation
TriSalus Life Sciences, Inc. (TLSI) reported Stock-Based Compensation of $5.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- TriSalus Life Sciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.62M, a 38.27% increase year-over-year.
- TriSalus Life Sciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.47M, a 52.59% increase year-over-year.
- TriSalus Life Sciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.20M, a 29.46% increase year-over-year.
- TriSalus Life Sciences, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.42M, a 147.43% increase year-over-year.
- TriSalus Life Sciences, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $9.13M, a 67.82% increase from fiscal 2024.
- TriSalus Life Sciences, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $5.44M, a 288.09% increase from fiscal 2023.
- TriSalus Life Sciences, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.40M, a 280.98% increase from fiscal 2022.
- TriSalus Life Sciences, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $368.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.09M 10-Q · filed 2026-08-06 | $7.29M derived: sum of 3 quarters · filed 2026-08-06 | $10.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.47M 10-Q · filed 2026-05-12 | $4.67M derived: sum of 2 quarters · filed 2026-05-12 | $8.09M derived: sum of 3 quarters · filed 2026-05-12 | $9.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.62M derived: sum of 2 quarters · filed 2026-03-05 | $7.51M derived: sum of 3 quarters · filed 2026-08-06 | $9.13M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.31M derived: sum of 2 quarters · filed 2026-08-06 | $6.93M 10-Q · filed 2025-11-13 | $8.63M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.51M 10-Q · filed 2026-08-06 | $5.21M derived: sum of 3 quarters · filed 2026-08-06 | $6.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.62M 10-Q · filed 2026-05-12 | $3.32M derived: sum of 2 quarters · filed 2026-05-12 | $4.70M derived: sum of 3 quarters · filed 2026-05-12 | $5.97M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.08M derived: sum of 2 quarters · filed 2026-03-05 | $4.36M derived: sum of 3 quarters · filed 2026-03-05 | $5.44M 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.66M derived: sum of 2 quarters · filed 2025-11-13 | $3.74M 10-Q · filed 2025-11-13 | $4.74M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.36M 10-Q · filed 2025-08-12 | $3.36M derived: sum of 3 quarters · filed 2025-08-12 | $3.62M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.09M 10-Q · filed 2025-05-15 | $2.09M derived: sum of 2 quarters · filed 2025-05-30 | $2.35M derived: sum of 3 quarters · filed 2025-05-30 | $2.41M derived: sum of 4 quarters · filed 2025-05-30 |
| 2023-12-31 | $1.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-05-30 | $1.26M derived: sum of 2 quarters · filed 2025-05-30 | $1.33M derived: sum of 3 quarters · filed 2025-05-30 | $1.40M 10-K/A · filed 2025-05-30 |
| 2023-09-30 | $260.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $328.00K derived: sum of 2 quarters · filed 2024-11-14 | $402.00K 10-Q · filed 2024-11-14 | $519.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $68.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $142.00K 10-Q · filed 2024-08-14 | $259.00K derived: sum of 3 quarters · filed 2024-08-14 | |
| 2023-03-31 | $74.00K 10-Q · filed 2024-05-15 | $191.00K derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $117.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $368.00K 10-K · filed 2024-04-11 | ||
| 2022-09-30 | $251.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |